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Background: Elderly patients with somatic symptom disorder (SSD) put a great burden on 
the health care delivery system. Cognitive behavioral therapy (CBT) is effective in adults with 
SSD. However, no studies have been conducted yet into CBT for SSD in later life.
Objectives: We explored the feasibility of CBT for SSD in the elderly.
Methods: This is a prospective pilot study comparing two outpatient specialty mental health 
settings for adults (,60 years; n=13) and for elderly patients ($60 years; n=9) with SSD. 
Intervention was 18 structured, protocoled, and supervised CBT sessions. Outcomes were 
somatic symptoms, pain intensity, pain disability, quality of life, depressive symptoms, and 
generalized anxiety symptoms. Feasibility of the CBT intervention was explored with self-
developed questions, both for the therapists and the patients.
Results: Both therapists and elderly patients evaluated the treatment as positive. Somatic 
symptoms improved significantly in the adult group but not in the elderly group. There was 
a large, significant decrease in pain intensity and pain disability in elderly patients compared 
to the adults. Social functioning, vitality, and anxiety symptoms improved significantly in the 
adults. Presence of chronic medical conditions did not influence these results.
Conclusion: This study shows that CBT is feasible as a treatment for SSD in older adults and 
has encouraging results. Replication in an RCT is warranted.
Keywords: somatic symptom disorder, somatoform disorder, pain, elderly, medically unex-
plained symptoms
Introduction
Somatic symptom disorders (SSDs) place a great burden on the health care delivery 
system. An estimation of the prevalence of SSD in adults is 19%.1 SSD was introduced 
with DSM-51 to replace the DSM-IV2 concept of somatoform disorders. The revised 
classification removes any reference to symptoms as medically unexplained3 and 
operationalizes the psychological concomitants of SSDs.4 The psychological 
concomitants of somatic symptoms are distressing and dysfunctional cognitions, 
emotions, and behaviors related to these bodily sensations, which are excessive and 
disproportional. Due to the physical presentation, individuals suffering with somatic 
symptoms initially seek help from a physician. Usually after many investigations, 
these individuals are referred to a psychiatrist. The prevalence of SSD in older adults is 
unknown, but considering the higher somatic comorbidity in later life, it is most likely 
that SSD is more common than the prevalence of somatoform disorders among the 
elderly, which is known to be somewhere in between 1.5 and 13%.5,6 A recent study 
revealed that quality of life was similarly affected in both older patients with medically 
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explained and medically unexplained symptoms when 
corrected for somatization and hypochondriacal cognitions, 
which supports the relevance of the DSM-5 classification 
of SSD for older adults.7 The authors call for appropriate 
psychological treatment to improve quality of life in older 
SSD patients.
Cognitive behavioral therapy (CBT) has been found 
efficacious in the treatment of SSD in younger cohorts.8–10 
We assume that SSD might even be more complex in older 
adults because of the higher somatic comorbidity in later life. 
CBT has been proven to have an almost similar efficacy in 
the treatment of depression and anxiety disorders in older 
adults up to the age of 80 years as in younger age groups.11–15 
However, CBT as a treatment for SSD in older adults has 
not been explored yet.
Objectives
Because of the lack of research on treatment of SSD in older 
adults, the central objective of our study was to explore the 
feasibility of individual CBT for the treatment of SSD in 
older adults. We explored
1. Whether individual CBT in older adults is associated with 
a reduction in somatic symptoms compared to adults?
2. Whether individual CBT in older adults is associated with 
a reduction in pain intensity and disability, anxiety, and 
depressive symptoms and an increase in quality of life 
compared to adults?
3. How treatment effects of CBT in older adults compare 
with treatment effects of CBT in adults with SSD?
4. What the influence is of chronic somatic comorbidity?
We hypothesized CBT to be feasible in elderly SSD 
patients. We expected a reduction in somatic symptoms, 
pain, generalized anxiety, and depressive symptoms and an 
increase in quality of life in older adults.
Methods
Participants
All participants were patients with SSD who were referred 
between January 2015 and August 2016 to GGz Breburg, 
an institute for mental health care in the Netherlands. 
The elderly patients aged 60 years and older were treated 
in the Department of Geriatric Psychiatry. The adult 
patients younger than 60 years were treated in the Clinical 
Center of Excellence for Body, Mind and Health (CBMH). 
Participants were included if they met the criteria for an 
SSD diagnosis as assessed with a psychiatric DSM-5 
interview. Exclusion criteria were major neurocognitive 
disorder (Mini–Mental State Examination16 score #23), 
substance dependence, and IQ ,80. Comorbidity with other 
mental disorders was allowed as long as SSD was the primary 
diagnosis. A concurrent somatic or psychological treatment 
was not allowed during the CBT treatment.
Measures
Feasibility of the intervention
Feasibility of the CBT intervention was explored with 
self-developed questions, both for the therapists and the 
patients. Questions concerned different qualitative aspects 
of the treatment, such as subjective efficacy of the treat-
ment, susceptibility for the patient, time investment, and 
emotional burden.
Physical complaints inventory (Pci)
Somatic symptoms were assessed with the Dutch PCI,17 
a 51-item self-report measure with a 4-point Likert scale 
(range 0–153). The reliability of the PCI is satisfactory 
(Cronbach’s α: 0.88).18
Brief Pain inventory (BPi)
Pain intensity and pain disability were assessed with two 
subscales of the BPI,19 the pain intensity subscale (four 
items), and limitations because of pain (seven items).20 
The BPI has an 11-point Likert scale (range 0–10). Reliability 
of both subscales is satisfactory (pain intensity, Cronbach’s 
α: 0.85; disability, Cronbach’s α: 0.88).21
Medical Outcomes study 36-items short Form 
health survey (sF-36)
Quality of life was assessed with the Medical Outcomes 
Study SF-36,22 a 36-item self-report measure. This survey 
assesses the following eight dimensions: vitality, physical 
functioning, bodily pain, general health perceptions, physi-
cal role functioning, emotional role functioning, social role 
functioning, and mental health. Reliability and validity have 
been found to be satisfactory and good, respectively.23
Patient health Questionnaire-9
Depressive symptoms were measured using the Patient 
Health Questionnaire-9 (PHQ-9),24 a 9-item self-report 
measure with a 4-point Likert scale. Reliability and validity 
are good.24
generalized anxiety Disorder 7-item (gaD-7) scale
Generalized anxiety was assessed using the GAD-7 scale,25 a 
7-item self-report questionnaire with a 7-point Likert scale. 
Reliability and validity were found to be good.25
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somatic comorbidity
Presence of somatic comorbidity was determined by a physi-
cal examination prior to start of treatment. This included the 
physical record provided by the patients’ GPs. Furthermore, 
the amount of somatic diseases was cross-checked with the 
Health Interview Questionnaire (HIQ).26 The HIQ is devel-
oped by the Dutch Central Agency of Statistics.
intervention
The individual CBT was a CBT protocol for medically 
unexplained symptoms, which has been found efficacious in 
adults with an average age of 36 years.8 The main therapeutic 
techniques used included identification and modification of 
dysfunctional automatic thoughts and behavioral experiments 
aimed at breaking the vicious cycle of the symptoms and 
their consequences. The original treatment protocol varied 
between 6 and 16 weekly sessions, depending on the severity 
of the problem and the number of maintaining consequences. 
In this study, we decided for a treatment dosage of 18 weekly 
sessions, divided into sets of six sessions. After each set of 
sessions, the PCI and BPI were taken and discussed with 
the patients to monitor the treatment. Treatment could be 
terminated earlier, that is after each set of six sessions, if 
patient and therapist agreed that optimal symptom reduc-
tion was achieved, and this was supported by the outcome 
of the measures.
Procedure
Patients with a primary diagnosis of SSD, who met the 
inclusion criteria, were approached by the first author. 
Potential participants were fully informed about the study 
and gave written consent to participate. The elderly partici-
pants were examined by a geriatrician, and the adult patients 
were examined by physicians of the CBMH. Therapists were 
11 psychologists, trained in CBT. Each therapist treated 
one to five patients (median: two patients per therapist). On 
average, the therapists had 8.5 years of experience in CBT. 
Experience did not differ between both treatment groups. 
Treatment integrity was monitored by means of supervision 
by the fourth author, who is experienced in the CBT protocol 
for SSD. Feasibility of the CBT intervention was explored 
3 months after the treatment was finished.
Design
For assessing the feasibility, we explored the effects of 
the protocoled individual CBT treatment in a prospective 
comparative pilot study between a group of elderly SSD 
patients and a group of adults SSD patients. Measures were 
taken four times: at start of treatment and after 6, 12, and 18 
CBT sessions. At baseline and end of treatment, all measures 
were taken. During the intermediate assessments, only the 
PCI and the BPI were taken. When it was decided to end 
treatment earlier because of optimal symptom reduction, the 
final assessment was done. The Medical Ethics Committee 
of Brabant and the local research ethics committee of GGz 
Breburg granted ethical approval.
statistics and data analysis
To determine differences between the groups in sociode-
mographic and clinical characteristics, χ2 and Fisher’s exact 
tests were conducted for categorical variables and t-tests and 
Mann–Whitney U-tests were conducted for (nonnormally 
distributed) continuous variables. In the latter case, median 
and interquartile range (IQR) were reported. Differences 
between baseline and end of treatment assessments were 
analyzed using Wilcoxon signed-rank tests for paired data. 
Furthermore, differences in change scores between the 
elderly and the adults were analyzed using Mann–Whitney 
U-tests. To interpret the size of the treatment effect, 
correlation coefficients (r) were computed. An r of 0.1 is 
considered as a small effect, 0.3 a medium effect, and $0.5 
a large effect.27
Finally, a mixed model analysis (including a random 
intercept) was conducted to examine the effect of CBT on 
number and intensity of somatic symptoms (time effect) and 
the differences in treatment effect of CBT between the elderly 
and the adults (time × group interaction). This analysis was 
repeated for pain intensity and pain disability. The results 
were adjusted for the number of chronic medical condi-
tions and standardized somatic symptom score at baseline. 
We report βs and the corresponding 95% CI of the time 
effect and the interaction effect. Analyses were conducted 
on the full sample (intention to treat analysis). For this aim, 
missing data were imputed through last observation carried 
forward (LOCF) imputation. Next, analyses were repeated 
including only those participants who completed the treat-
ment (completers analysis).
Results
Patient flow
Figure 1 shows the patient flow. After screening, 11 elderly 
and 16 adult patients were eligible. In the intention to treat 
analysis, 9 elderly patients and 13 adult patients were included. 
Finally, 7 elderly and 12 adults finished the study and were 
included in the completers analysis. The number of treatment 
sessions varied between 5 and 18 (median: 15 sessions). 
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The elderly patients received less sessions (median: 14; 
range: 6–18) than the adult patients (median: 16; range 6–18). 
This difference however is not significant (MWU[21] =72.0; 
P=0.069).
Table 1 describes the demographic and clinical charac-
teristics of both groups at the start of treatment. All elderly 
patients reported at least one chronic medical condition, 
compared to only 62% of the adult patients (8/13). None 
of the elderly patients had less than two comorbid medical 
conditions (range 2–4). These differences between the elderly 
group and the adult group were significant. Most elderly 
patients suffered from pain. Mood disorders were also preva-
lent. Most elderly patients used antidepressant, anxiolytic, 
and pain medications. A total of 30% of the elderly and 
8% of the adults ended treatment earlier than the maximum 
of 18 sessions. This difference was not significant.
Table 2 shows the scores on all measures at start of treat-
ment. Both groups reported high levels of somatic symptoms, 
pain, anxiety, and depressive symptoms and a low quality of 
life. There were no differences between the elderly and the 
adults except for lower general health perceptions.
Treatment effects
Tables 3 and 4 show the effects of the CBT treatment for the 
elderly and the adults. Small to medium effects were found 
for somatic symptoms in both groups. These treatment effects 
did not differ significantly between the groups. Reduction in 
somatic symptoms was significant for the adults.
Treatment effect on pain intensity was large for the 
elderly but small and not significant for the adults. The 
difference between these two effects was medium. Pain 
disability significantly decreased in the elderly group but 
not in the adult group.
Treatment effects on aspects of quality of life were small 
to medium. Again, on the pain intensity subscale, there was a 
significant medium effect in the elderly. The adults improved 
mainly on the subscales, such as social functioning and 
vitality. Differences on quality of life were not significant 
however between the two groups.
Both groups improved with a small-to-medium effect size 
on depressive symptoms and with a medium-to-large effect 
size on anxiety. Treatment effects on anxiety and depressive 
symptoms did not differ between the elderly and the adults.
Figure 1 Patient flow.
Abbreviation: ssD, somatic symptom disorder.
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The qualitative evaluation revealed that the therapists 
evaluated five out of six aspects of the CBT protocol as posi-
tive for the elderly patients. The elderly patients themselves 
evaluated all aspects of treatment as positive and rated the 
treatment with 8 out of 10.
We applied a mixed model analysis to further analyze 
the effects of treatment (N=23: ITT analysis), controlling for 
the presence of chronic medical conditions and the severity 
of complaints at the start of treatment. There appeared to 
be no independent effect of CBT on somatic symptoms 
(β=-0.75; 95% CI: -2.05 to 0.56, P=0.26). Moreover, there 
was no significant difference between the course of treat-
ment of the elderly and the adults (β=-0.16; 95% CI: -2.45 
to 2.13, P=0.89).
Also for pain intensity, CBT did not have an independent 
effect (β=-0.34; 95% CI: -2.15 to 1.47, P=0.71). For pain 
Table 1 Demographic and clinical characteristics of both groups
Elderly, n=9 Adults, n=13 Statistical tests and 
P-values
Male, n (%)a 5 (56) 2 (15) FeT, P=0.07
age, M (sD)b 70.7 (8.2) 40.7 (11.2) T(20)=6.843; P,0.001*
education, n (%)b χ2(3)=2.836; P=0.42
elementary school 2 (29) 1 (8)
lower vocational training 3 (43) 4 (31)
higher secondary with vocational training 1 (14) 6 (46)
higher education 1 (14) 2 (15)
Missing 2
Primary complainta χ2(2)=0.972; P=0.62
Pain 6 (67) 6 (46)
Fatigue 1 (11) 3 (23)
Others 2 (22) 4 (31)
comorbid axis i disorders
Depressiona 4 (44) 4 (31) FeT, P=0.66
anxiety disordera 2 (22) 5 (39) FeT, P=0.65
Othersa 1 (11) 4 (31) FeT, P=0.36
No comorbiditya 3 (33) 5 (39) FeT, P=0.99
comorbid personality disordera χ2(1)=1.671; P=0.43
No 4 (44) 3 (23)
Yes 1 (12) 4 (31)
Traits 4 (44) 6 (46)
Duration current ssD (years)a FeT, P=0.99
,1 7 (78) 11 (85)
$1 2 (22) 2 (15)
history of ssD FeT, P=0.38
First episode 7 (78) 7 (54)
Previous episodes 2 (22) 6 (46)
somatic comorbidity
Yesc 9 (100) 8 (62) χ2(1)=4.480, P=0.03*
Number of diseases, median (iQr)d 3 (2–3) 1 (0–2) U=18.5, P=0.005*
Number of appointments with health practitioners 
over the last 3 months (Tic-P), median (iQr)d
13.5 (11.5–18.5) 13.0 (4.5–22.5) U=27.5, P=0.42
Nmissing 1 4
Psychiatric admittance past 12 monthsa 1 (11) 1 (8) FeT, P=0.99
Medication
antidepressantsa 7 (78) 8 (62) FeT, P=0.65
anxiolyticsa 5 (56) 5 (23) FeT, P=0.19
sleep medicationa 1 (11) 2 (15) FeT, P=0.99
Pain medicationa 4 (44) 2 (15) FeT, P=0.18
Other medicationsa 1 (11) 6 (42) FeT, P=0.16
Dietary supplementsa 0 (0) 2 (15) FeT, P=0.94
Notes: Other comorbid axis i disorders: aD(h)D, minor neurocognitive disorder, and autism. Other medications: antipsychotics and anticonvulsants. aP-values obtained 
with Fisher’s exact test; percentage between parentheses. bP-values obtained with independent t-test; percentage between parentheses. cP-values obtained with χ2 test; 
percentage between parentheses. dP-values obtained with Mann–Whitney U-test; percentage between parentheses. *Significant to P,0.05.
Abbreviations: AD(H)D, Attention Deficit (Hyperactivity) Disorder; FET, Fisher’s exact test; IQR, interquartile range; SSD, somatic symptom disorder; Tic-P, Toronto 
institute for contemporary Psychoanalysis.
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Table 3 change scores (T1–T4) for elderly and adults
Elderly (n=9) Adults (n=13) Elderly vs adults
Difference T1–T4, 
median (IQR)
Testa Difference T1–T4, 
median (IQR)
Testa Testb
somatic symptoms (Pci) -2.0 (-6.0 to 2.5) Z=14.5, P=0.62 -2.0 (-6.5 to 1.0) Z=11.5, P=0.05 U=50, P=0.60
Pain (BPi)
Pain intensity -5.0 (-15.0 to -3.5) Z=0, P=0.011* 0.0 (-9.5 to 6.0) Z=32, P=0.58 U=86, P=0.07
Disability -9.0 (-22.5 to -3.0) Z=0, P=0.012* -4.0 (-7.5 to 3.0) Z=24, P=0.24 U=83.5, P=0.10
Quality of life (sF-36)
general health perceptions 0.0 (-2.0 to 2.5) Z=10, P=0.92 -1.0 (-5.5 to 1.0) Z=14.5, P=0.18 U=43.5, P=0.32
emotional role functioning 0.0 (-1.0 to 0.0) Z=0, P=0.10 0.0 (-1.0 to 0.0) Z=8.5, P=0.67 U=66.5, P=0.60
Physical role functioning 0.0 (-1.0 to 0.0) Z=4, P=0.71 0.0 (-2.0 to 0.0) Z=0, P=0.07 U=51.5, P=0.65
Physical functioning 0.0 (-5.0 to 5.0) Z=5, P=0.99 -1.0 (-2.5 to 1.0) Z=20, P=0.44 U=45, P=0.39
Mental health 0.0 (-4.5 to 0.0) Z=1.5, P=0.10 -2.0 (-3.5 to 1.0) Z=13, P=0.07 U=59.5, P=0.95
Bodily pain -1.0 (-2.5 to 0.0) Z=0, P=0.041* 7.0 (5.5 to 9.0) Z=9, P=0.06 U=57.5, P=0.95
social role functioning 0.0 (-2.5 to 0.0) Z=0, P=0.07 -2.0 (-3.0 to 0.0) Z=8, P=0.045* U=51.5, P=0.65
Vitality 0.0 (-2.0 to 0.0) Z=2, P=0.27 -1.0 (-5.5 to 0.0) Z=0, P=0.007* U=34, P=0.11
Depressive symptoms (PhQ-9) 0.0 (-3.5 to 2.0) Z=9, P=0.75 -4.0 (-8.5 to 1.5) Z=15, P=0.06 U=42.5, P=0.29
anxiety symptoms (gaD-7) -1.0 (-9.5 to 0.0) Z=2, P=0.07 -2.0 (-5.5 to 0.0) Z=7, P=0.036* U=58, P=1.00
Notes: aTest of paired T1–T4 measurement with Wilcoxon signed-rank tests. bTest of change score between elderly and adults with Mann–Whitney U-tests. *Significant 
to P,0.05.
Abbreviations: BPI, Brief Pain Inventory; GAD-7, Generalized Anxiety Disorder 7-item scale; IQR, interquartile range; PCI, Physical Complaints Inventory; PHQ-9, Patient 
health Questionnaire-9; sF-36, 36-items short Form health survey.
Table 2 scores at start of treatment
Elderly (n=9), median (IQR) Adults (n=13), median (IQR) Difference between groupsa
somatic symptoms (Pci) 25.0 (5.0–37.5) 15.0 (9.5–18.5) U=43.5, P=0.324
Pain (BPi)
Pain intensity 21.0 (21.0–24.0) 23.0 (17.0–29.0) U=70, P=0.471
Disability 34.0 (26.5–46.5) 37.0 (16.0–51.0) U=58, P=0.999
Quality of life (sF-36)
general health perceptions 14.0 (11.0–18.5) 19.0 (16.5–22.0) U=91, P=0.030*
emotional role functioning 6.0 (4.5–6.0) 6.0 (5.0–6.0) U=62, P=0.849
Physical role functioning 8.0 (5.0–8.0) 8.0 (8.0–8.0) U=74, P=0.324
Physical functioning 21.0 (13.0–25.0) 17.0 (12.5–26.0) U=54.5, P=0.794
Mental health 20.0 (19.0–24.0) 18.0 (13.5–23.5) U=39.5, P=0.209
Bodily pain 7.00 (5.5–8.5) 8.00 (5.0–10.5) U=75.5, P=0.262
social role functioning 7.0 (5.5–8.0) 6.0 (6.0–9.0) U=63, P=0.794
Vitality 15.0 (11.5–18.0) 20.0 (17.0–21.5) U=88, P=0.051
Depressive symptoms (PhQ-9) 13.0 (6.0–19.0) 11.0 (9.5–18.5) U=70.5, P=0.431
anxiety symptoms (gaD-7) 14.0 (8.0–19.5) 11.0 (6.5–13.0) U=39.5, P=0.209
Notes: aP-values obtained with Mann–Whitney U-tests. *Significant to P,0.05.
Abbreviations: BPI, Brief Pain Inventory; GAD-7, Generalized Anxiety Disorder 7-item scale; IQR, interquartile range; PCI, Physical Complaints Inventory; PHQ-9, Patient 
health Questionnaire-9; sF-36, 36-items short Form health survey.
intensity, there appeared to be a significant difference in 
the course of treatment between the elderly and the adults 
(β=-3.54; 95% CI: -6.61 to -0.47, P=0.024) in favor of the 
elderly. There was no independent treatment effect for pain 
disability (β=-1.73; 95% CI: -4.17 to 0.71; P=0.16), and the 
difference in the course of treatment between both groups was 
not significant (β=-3.29; 95% CI: -7.46 to 0.89, P=0.12). 
When we repeated these analyses for the patients who 
completed treatment, we found similar results. The course 
of treatment is represented in Figure 2A–C. The severity of 
symptoms is represented against the course of treatment. 
T1–T4 represent start of treatment, measurement after 
6 weeks, after 12 weeks, and end of treatment, respectively.
Discussion
As this was the first study on treatment of SSD in later life, 
our main objective was to explore the feasibility of individual 
CBT in elderly patients with SSD compared to adults with 
SSD. Both patients and therapists evaluated the CBT protocol 
as positive for the elderly patients. The elderly patients rated 
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Table 4 Size of treatment effect (T1–T4) on each measure in correlation coefficient (r)
Elderly Adults Elderly vs adults
Results from 
intention to 
treat analysis
Results from 
completers 
analysis
Results from 
intention to 
treat analysis
Results from 
completers 
analysis
Results from 
intention to 
treat analysis
Results from 
completers 
analysis
somatic symptoms (Pci) 0.08 0.32 0.23 0.25 0.16 0.09
Pain (BPi)
Pain intensity 0.55* 0.63* 0.11 0.12 0.38 0.44
Disability 0.39* 0.58* 0.11 0.09 0.37 0.37*
Quality of life (sF-36)
general health perceptions 0.01 0.08 0.25 0.25 0.25 0.27
emotional role functioning 0.18 0.34 0.04 0.03 0.18 0.26
Physical role functioning 0.01 0.06 0.32 0.29 0.35 0.26
Physical functioning 0.01 0.12 0.10 0.06 0.15 0.16
Mental health 0.23 0.47 0.18 0.20 0.04 0.12
Bodily pain 0.29* 0.42* 0.23 0.21 0.01 0.09
social role functioning 0.34 0.50 0.38* 0.38* 0.08 0.00
Vitality 0.09 0.28 0.42* 0.44* 0.35 0.34
Depressive symptoms (PhQ-9) 0.08 0.27 0.30 0.32 0.20 0.16
anxiety symptoms (gaD-7) 0.30 0.60* 0.37* 0.39* 0.03 0.09
Note: *Significant to P,0.05.
Abbreviations: BPi, Brief Pain inventory; gaD-7, generalized anxiety Disorder 7-item scale; Pci, Physical complaints inventory; PhQ-9, Patient health Questionnaire-9; 
sF-36, 36-items short Form health survey.
Figure 2 (A) course of treatment for somatic symptoms. (B) course of treatment for pain intensity. (C) Course of treatment for pain disability. Scores and 95% confidence 
interval estimated using mixed model-analysis (including random intercept), adjusted for number of chronic medical conditions and standardized somatic symptoms score 
at baseline.
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the treatment with 8 out of 10. The observed effects on pain 
intensity, pain disability, and quality of life can be considered 
encouraging for the elderly. An explanation for the more 
limited effect on somatic symptoms might be that our elderly 
SSD patients suffered from more comorbid medical condi-
tions than their younger counterparts, which can account for 
a smaller margin of improvement than among the younger 
SSD patients. A higher somatic comorbidity among elderly 
SSD patients was also found in other studies.5,6 However, 
we did not find that amount of chronic medical conditions 
influenced treatment outcome.
The higher effects of CBT on the pain measures in the 
elderly patients are a finding that warrants further research. 
Eisenberger28 describes that there is emerging evidence, 
which suggests that experiences of social pain (the painful 
feelings associated with social disconnection) are experienced 
in the same way as physical pain and that they rely on the 
same neurobiological substrates. This phenomenon could be 
more prevalent in later life, as older adults are less engaged 
socially. Such a finding is corroborated by the combined 
improvement of social engagement and pain in our study. 
We found that social functioning improved significantly in 
the elderly, which could support the hypothesis that when 
CBT improves social functioning and integration in elderly 
SSD patients, this might enhance treatment effect on pain.
Overall, the treatment effects in this study are similar to 
the small to medium effects, which were found in studies 
on CBT for medically unexplained symptoms in adults.10 
The results of this pilot study are a first indication that 
CBT is feasible and associated with a positive treatment 
outcome treatment for SSD in later life. This is supported 
by the positive appraisal of the treatment by both patients 
and therapists.
limitations and strengths
An important limitation of this study is its small sample 
size. Because of the sample size, the differences in outcomes 
between the two samples could possibly be accounted for by 
other reasons than the age of the participants. Central aim of 
this pilot study was exploring the feasibility of CBT for SSD 
in older adults. Our findings seem to justify replication of 
these results in a larger study. Another limitation concerns 
the observational design and lack of randomization, which 
can only show effects over time; we cannot rule out that 
the observed changes may have other explanations, like 
natural illness course or regression to the mean. We suggest 
conducting a randomized trial in future research. A third 
limitation is the lack of follow-up measurements to assess 
whether the effects hold over time. A fourth limitation is the 
sampling of patients from two different wards: there may 
have been biases in the referral patterns. Hence, the popula-
tions may not be fully comparable. A fifth limitation is that 
the “elderly” patients were defined by a relatively young age 
of 60 years. Although the mean age of the elderly eventually 
was ~71 years, we cannot be sure whether this treatment is 
as feasible for the old–old, aged $80 years.
Strength of our study is the comparison of elderly patients 
with a group of adult patients with SSD to explore the dif-
ferences in elderly SSD patients. Considering our findings, 
especially those on pain intensity and pain disability, we 
suggest to explore in future research whether pain is asso-
ciated with social disconnection in later life and whether 
interventions that target this social connectedness enhance 
the treatment effect on pain in older adults.
Conclusion
This first study into the feasibility of CBT for the treatment 
of SSD in elderly patients provides us a preliminary indica-
tion that CBT is both applicable and potentially effective as 
a treatment for SSD in later life. Possibly, treatment of SSD 
in older adults should be focused more on the experiences 
and limitations of somatic symptoms than their reduction, 
considering a higher somatic comorbidity in later life. 
The role of social disconnection in pain and the options for 
enhancing treatment efficacy of SSD in later life deserve 
further research.
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